Generate Biomedicines (GENB) Shares Climbed, What Is Driving Attention Now?

Anthropic’s push into drug development, including its collaboration with Generate Biomedicines (GENB) on AI designed CAR T-cell therapies, puts this US biotech in focus for investors watching AI driven approaches to complex diseases.

Recent trading has picked up meaningfully, with a 7 day share price return of 23.3% and a 90 day share price return of 12.6% lifting Generate Biomedicines to $15.77. The more modest 30 day share price return of 2.3% suggests fresh momentum has been building mainly in the past week as investors react to the Anthropic collaboration and broader interest in AI driven drug development.

Scan other AI focused healthcare plays showing similar momentum with our curated list of 36 healthcare AI stocks alongside Generate Biomedicines.

Bulls see Generate Biomedicines as an AI drug discovery leader now riding fresh momentum, while bears point to heavy losses and early stage programs. Which story do the current numbers lean toward as you assess valuation next?

Most Popular Narrative: 42% Undervalued

Generate Biomedicines closed at $15.77 versus a widely followed fair value narrative of $27, which frames the recent price strength as only a partial catch up to that thesis.

Amgen and Novartis partnerships across nine difficult protein targets, with per program milestones in the mid to upper US$300 million range and royalty rates in the mid single to low double digits, together with expected milestones over the next 12 to 18 months, provide potential non dilutive cash inflows that could support earnings and extend Generate Biomedicines’ balance sheet beyond current cash funding through the first part of 2028.

See why 3 investors see Generate Biomedicines as 42% undervalued.

Result: Fair Value of $27 (UNDERVALUED)

Still, two pressure points could flip that undervalued story: heavier than expected cash burn that forces extra equity raising, and tougher U.S. drug pricing curbing GB-0895 economics.

Find out about the key risks to this Generate Biomedicines narrative.

Next Steps

Mixed signals on Generate Biomedicines so far. Use the data, pressure test both sides of the story, then weigh the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Generate Biomedicines?

If you are serious about building a stronger portfolio, do not stop at one AI healthcare opportunity. Broaden your watchlist with targeted screeners that surface stocks built on clear fundamentals, resilient balance sheets, and differentiated income profiles.

• Zero in on potential mispricings by scanning a focused set of 30 high quality undervalued stocks that pair strong fundamentals with prices the market has yet to fully reflect.
• Strengthen your income stream by reviewing 7 dividend fortresses that combine higher yields with characteristics designed to support more reliable payouts.
• Protect the downside by filtering for 30 resilient stocks with low risk scores that score well on resilience and aim to keep surprises to a minimum.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com